Pioneering study of Egyptian Neem and Jojoba extracts with molecular docking combat hospital multidrug resistant bacteria
- PMID: 39775688
- PMCID: PMC11885210
- DOI: 10.1007/s42770-024-01590-w
Pioneering study of Egyptian Neem and Jojoba extracts with molecular docking combat hospital multidrug resistant bacteria
Abstract
Hospital surfaces are often contaminated with multidrug-resistant pathogenic bacteria that cause healthcare-associated infections and lead to increased mortality and morbidity. There is a need for new alternative antibacterial agents to overcome antibiotic resistance. Azadirachta indica and Simmondsia chinensis have been found to possess antibacterial activity and medicinal value. The antibacterial activity of these plant extracts against clinical isolates was investigated using the agar disc diffusion method. These clinical isolates included E. coli, Pseudomonas aeruginosa, Acinetobacter spp., Klebsiella pneumoniae, Stenotrophomonas maltophilia, and methicillin-resistant Staphylococcus aureus (MRSA), which were identified by the vitek-2 system, and resistance genes of selected bacterial strains were identified by using the bioFire FilmArray test. The most potent extract of these plants was the ethanolic extract, where the inhibition percentage of ethanolic Jojoba and Neem extracts was 90.9% and 74.5%, respectively against all the tested pathogens. On the other hand, the methanolic extracts of Neem and Jojoba have different degrees of antibacterial activity against the tested pathogens. The phytochemical components of the most potent extracts (ethanolic extracts) were investigated by gas chromatography‒mass spectrometry (GC\MS), which revealed that the ethanolic extracts were enriched in phenolics, flavonoids, and sugars. FTIR analyses of the plant extracts confirmed the presence of alcoholic, carboxylic, and aldehydic moieties. The 2,2-diphenyl-1-picrylhydrazyl (DPPH) activity of the ethanolic extracts of Neem and Jojoba increased in a dose-dependent manner, with average IC50 values of 98.17 ± 0.85, 4.95 ± 0.06, and 4.17 ± 0.04 mg/mL, respectively, for the ethanolic Neem extract, the ethanolic Jojoba extract, and ascorbic acid (standard). Furthermore, increased cytotoxicity was demonstrated in the HFB4 cell line in a dose-dependent manner. The average IC50s of the ethanolic Neem extract and the ethanolic Jojoba extract were 18.18 ± 0.15 and 76.16 ± 1.49 mg/mL, respectively. Moreover, the results for the antibiofilm activity of the ethanolic Neem extract showed that 99.5% of the biofilms formed at 25 mg/ml. In addition, 50 mg/ml of the ethanolic extract of Jojoba had a suppressive effect of 98.2%. The significant components Nonanoic acid (21.9405%) and Palmitic Acid (16.0869%) from Neem and pinitol from Jojoba (82.85%) were selected throughout the molecular docking investigation, by which the chosen constituents inhibited the crystal structure of penicillin-binding protein 4 (PBP4) from Staphylococcus aureus (PDB ID: 1TVF) and the crystal structure of the OXA-48 beta-lactamase (PDB ID: 7AUX) from K. pneumoniae. Overall, our study reveals the effectiveness of antimicrobial plant extracts as therapeutic solutions for antibiotic resistance in Egypt and worldwide with some modifications to decrease their cytotoxicity.
Keywords: Azadirachta indica; Simmondsia chinensis; Antibacterial; Healthcare-associated infections; Molecular docking and multidrug resistant bacteria; Multidrug resistant bacteria.
© 2024. The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia.
Conflict of interest statement
Declarations. Competing interest: All the authors declare no conflicts of interest.
Similar articles
-
Biochemical Screening, In-vitro and In-silico Characterization of Citrullus colocynthis Fruit Extracts: A Combined Experimental and Computation Study.Curr Pharm Biotechnol. 2025;26(9):1392-1416. doi: 10.2174/0113892010332012241027022502. Curr Pharm Biotechnol. 2025. PMID: 39492776
-
Phytochemical profile and antimicrobial activity of individual frond extracts of Menisorus pauciflorus, Pteris catoptera, Conniogramme africana and Antrophyum mannianum.BMC Complement Med Ther. 2025 Jul 12;25(1):262. doi: 10.1186/s12906-025-05003-9. BMC Complement Med Ther. 2025. PMID: 40652226 Free PMC article.
-
Antibacterial Activity of CuO Nanoparticles, Ethanolic Extract of Amphipterygium adstringens, and Their Combination Against Multidrug-Resistant Bacteria.Int J Nanomedicine. 2025 Jun 23;20:8003-8022. doi: 10.2147/IJN.S517465. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40584782 Free PMC article.
-
A systematic review on natural products with antimicrobial potential against WHO's priority pathogens.Eur J Med Res. 2025 Jul 1;30(1):525. doi: 10.1186/s40001-025-02717-x. Eur J Med Res. 2025. PMID: 40597250 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Raja SN, Tsermang C (2021) Multidrug-resistant infections: a growing global threat. J Glob Health 11:01001 - PubMed
-
- Lax S, Gilbert JA (2015) Hospital-associated microbiota and implications for nosocomial infections. Trends Mol Med 21:427–432 - PubMed
-
- Kluytmans-van den Bergh MFQ, Bruijning-Verhagen PCJ, Vandenbroucke-Grauls CMJE, de Brauwer EIGB, Buiting AGM, Diederen BM, van Elzakker EPM, Friedrich AW, Hopman J, Al Naiemi N et al (2019) Contact precautions in single-bed or multiple-bed rooms for patients with extended-spectrum ßLactamase-producing enterobacteriaceae in Dutch Hospitals: a ClusterRandomised, crossover, non-inferiority study. Lancet Infect Dis 19:1069–1079 - PubMed
-
- Maechler F, Schwab F, Hansen S, Fankhauser C, Harbarth S, Huttner BD, Diaz-Agero C, Lopez N, Canton R, Ruiz-Garbajosa P et al (2020) contact isolation versus standard precautions to decrease acquisition of extended-spectrum B-Lactamase-producing enterobacterales in non-critical care wards: a clusterrandomized crossover trial. Lancet Infect Dis 42(20):575–584 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous